Cellectis S.A. has made a significant announcement regarding its gene therapy product, .HEAL-101, which targets APOC3 to reduce triglyceride levels. The company presented preclinical data at the European Society of Gene and Cell Therapy (ESGCT) conference, indicating a potential breakthrough in treatment for severe hypertriglyceridemia (sHTG). This development highlights Cellectis's commitment to advancing genetic medicines and positions the company as a notable player in the biological products industry.

Founded in Paris, Cellectis S.A. operates in the biological products sector, specifically focusing on gene therapies. The company is listed on both the Nasdaq under the ticker CLLS and Euronext Growth under ALCLS. Cellectis has been actively filing reports with the SEC, including a recent filing on October 28, 2026, detailing its latest developments.

The filing reveals that on October 26, 2026, Cellectis issued a press release highlighting the presentation of preclinical data for .HEAL-101. The product is designed to permanently inactivate APOC3, a known driver of elevated triglycerides, through a single intravenous administration. The data presented at ESGCT showed a 70% in vivo editing rate of human APOC3 and a 76% reduction in triglyceride levels in a murine disease model.

Julien Valton, Ph.D., Vice President of Gene Therapy at Cellectis, stated, “These expanded preclinical data reinforce the potential of our TALE base editing approach to achieve efficient and specific APOC3 editing following a single administration.” This statement underscores the company's confidence in the efficacy of .HEAL-101 as a potential one-time treatment for patients suffering from severe hypertriglyceridemia.

The findings from this research could have far-reaching implications for patients with hypertriglyceridemia, as well as for the broader industry. The ability to effectively edit genes and reduce triglyceride levels could pave the way for new therapies that require less frequent administration, thus improving patient compliance and outcomes.

Cellectis's advancements may also impact competitors in the biological products sector, as they may need to accelerate their own research and development efforts in response to Cellectis's promising results. As the industry continues to evolve, companies focusing on genetic medicines will likely face increased pressure to innovate and deliver effective treatments.

Looking ahead, Cellectis plans to initiate a Phase 1 investigator-initiated trial in China, with preliminary clinical data expected in the second half of 2027. This step marks a significant milestone in the development of .HEAL-101 and could further validate the company's approach to gene therapy.

As Cellectis continues to advance its research and development initiatives, the company remains committed to providing lasting therapeutic solutions for diseases that currently require lifelong treatment. The ongoing developments in gene editing and therapy will be closely watched by industry stakeholders and patients alike.